UCB Study Highlights the Burden of Ocular Myasthenia Gravis @checkrare
UCB Study Highlights the Burden of Ocular Myasthenia Gravis  @checkrare
Uploaded November 2026 | Updated November 2026, 4 days ago
Biopharmaceutical company UCB recently shared findings from a mixed-methods study examining the experiences and unmet needs of people living with ocular myasthenia gravis (oMG). The findings were presented at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session.

Anna Kole, Global Patient Engagement Lead for Myasthenia Gravis at UCB, discusses the findings and explains how patient perspectives could improve clinical research and care.
UCB Study Highlights the Burden of Ocular Myasthenia GravisGambling on Clinical TrialsMolecular Changes Associated With Teprotumumab Treatment in Thyroid Eye DiseaseMiv-cel Shows Durable Results in Stiff Person Syndrome and Myasthenia GravisNarcolepsy Awareness MonthFirst-Line Therapy Approved for Rare Lung Cancer  Safety and Efficacy of Kygevvi in Thymidine Kinase 2 DeficiencyPredicting Treatment Response Outcomes With Proteomic and Machine Learning Analyses in MGDiagnostic Delay in Endocrine DisordersNeuroblastoma: The Children’s Oncology GroupGetting a Rare Disease Drug Approved Is Only Half the Battle | The CheckRare Brief Ep 4Gambling on Clinical Trials
CheckRare |

UCB Study Highlights the Burden of Ocular Myasthenia Gravis

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER